Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,504 active trials253 approved drugs3,568 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,622 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT03620903 | Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia | active not recruiting | Phase 2 | 53 | Christian BuskeOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | active not recruiting | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05065554 | ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy | active not recruiting | Phase 2 | 12 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | active not recruiting | Phase 2 | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer(WIN-B) | active not recruiting | Phase 1 / Phase 2 | 76 | MedSIROTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT07267286 | Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） | active not recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT01991379 | MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) | active not recruiting | Phase 1 / Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02066220 | International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | active not recruiting | Phase 2 / Phase 3 | 360 | Universitätsklinikum Hamburg-EppendorfOTHER | 16 | Dec 4, 2025 | clinicaltrials |
| NCT03212742 | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients(OLA-TMZ-RTE-01) | active not recruiting | Phase 1 / Phase 2 | 91 | Centre Francois BaclesseOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03618537 | Ixazomib Maintenance Study in Patients With AL Amyloidosis | active not recruiting | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05189457 | First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | active not recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04963946 | STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia(STAIR) | active not recruiting | Phase 2 | 160 | French Innovative Leukemia OrganisationOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03834961 | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | active not recruiting | Phase 2 | 33 | Children's Oncology GroupNETWORK | 2 | Dec 2, 2025 | clinicaltrials |
| NCT04174196 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | active not recruiting | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05433116 | Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC | active not recruiting | Phase 2 | 50 | Universität des SaarlandesOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05659251 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06100367 | 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours | active not recruiting | Phase 2 / Phase 3 | 100 | Changi General HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07160647 | The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)(Neo-IT) | active not recruiting | Phase 2 | 29 | Sir Run Run Shaw HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257575 | A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | active not recruiting | Phase 2 | 138 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05975307 | Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation(BCIRT-01) | active not recruiting | Phase 2 | 71 | Sun Yat-sen UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer(Triple-B) | active not recruiting | Phase 2 | 304 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02570542 | Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04940325 | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer(ICARUS-LUNG01) | active not recruiting | Phase 2 | 100 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03687957 | rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide | active not recruiting | Phase 1 / Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07247383 | Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma | active not recruiting | Phase 2 | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02866136 | Conservative Treatments of Retinoblastoma(RETINO2011) | active not recruiting | Phase 2 | 133 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03718767 | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | active not recruiting | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03233152 | A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.(GlitIpNi) | active not recruiting | Phase 1 / Phase 2 | 110 | Universitair Ziekenhuis BrusselOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07127497 | Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT02333435 | Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life(RCT-EPA) | active not recruiting | Phase 2 | 130 | CHU de Quebec-Universite LavalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04250922 | LAM561 With RT and TMZ for Adults With Glioblastoma(CLINGLIO) | active not recruiting | Phase 2 / Phase 3 | 144 | Laminar PharmaceuticalsINDUSTRY | 5 | Nov 20, 2025 | clinicaltrials |
| NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC(ETNT) | active not recruiting | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT05176002 | Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. | active not recruiting | Phase 1 / Phase 2 | 25 | Fujian Medical University Union HospitalOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy(BladderSpar) | active not recruiting | Phase 2 | 79 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04070443 | Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase(TIPI) | active not recruiting | Phase 2 | 170 | Centre Leon BerardOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05781308 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy(ADAPTABLE) | active not recruiting | Phase 2 | 156 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer | active not recruiting | Phase 2 / Phase 3 | 669 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07232953 | Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia(FT14) | active not recruiting | Phase 2 | 82 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT01941641 | Colon Neoadjuvant FOLFOXIRI Study | active not recruiting | Phase 2 | 40 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03997435 | FOLFOXIRI With or Without Intensification for Rectal Cancer | active not recruiting | Phase 2 | 72 | CCTUOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT04386746 | Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer(GEMDOCE) | active not recruiting | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 17, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 5, 2025source: clinicaltrials